Hematopoietic growth factors in autologous transplantation

Biotherapy

Volumn 10, Issue 4, 1998, Pages 299-308

  Avanzi, Gian Carlo ^a   Gallicchio, Margherita ^a   Saglio, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Bone marrow transplantation; Granulocyte colony stimulating factor; Granulocyte monocyte colony stimulating factor; Hematopoietic growth factors; Hematopoietic stem cells; Peripheral blood progenitor cells transplantation

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR;

ARTICLE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; LEUKAPHERESIS; MOLECULAR CLONING; NEUTROPENIA; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION;

EID: 0031919181     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02678550     Document Type: Article

References (86)

1. Clark SC, Camen R. The human hematopoietic colony stimulating factors. Science 1987; 236: 1229-37.
2. Berardi A, Wang A, Levine JD, Lopez P, Scadden DT. Functional isolation and characterization of human hematopoietic stem cells. Science 1995; 267: 104-108.
3. + and CD34+ lin cells, and the generation of colony-forming cell progeny from cd 34+ lin cells cultured with IL-3, granulocytecolony stimulating factor, orgranulocyte-machrophage colony stimulating factor. Blood 1991; 77: 2316-24.
4. Cheng T, Shen H, Giokas D, Gere J, Tenen DG, Scadden DT. Temporal mapping of gene expression levels during the differentiation of individual primary hematopoietic cells. Proc. Natl. Acad. Sci. USA 1996; 93: 13258-63.
5. Andrews G, Knitter GH, Bartelmex SH, Langley KE, Farrar D, Hendren RW, Appelbaum FR, Bernstein ID, Zsebo KM. Recombinant human stem cell factor, a c-kit ligand, stimulates hematopoiesis in primates. Blood 1991; 78: 1975-83.
6. Huffman R, Tong J, Brandt J, Traycoff C, Bruno E, McGuire BW, Gordon MS, McNiece I, Srour EF. The in vitro and in vivo effects of stem cell factor on human hematopoiesis. StemCells-Dayt. 1993; 11 Suppl 2: 76-82.
7. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched population. Cell 1991; 65: 1143-48.
8. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J, Luh J, Duda G, Martina N, Peterson D, Menon S, Shanafelt A, Muench M, Keiner G, Namikawa R, Rennick D, Roncarolo MG, Zlotnik A, Rosnet O, Dubreuil P, Birnbaum D, Lee F. Ligand for FIt3/Flk2 receptor tyrosine kinase regulates growth of hematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368: 643-46.
9. Lyman SD, James L, Johnson L, Brasel K, deVries P, Escobar SS, Downey H, Splett RR, Beckmann MP, McKenna HJ. Cloning of the human omologue of the murine Flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 1994; 83: 2795-802.
10. Shah AJ, Smogorzewska EM, Hannum C, Crooks GM. Ftl3 ligand induces proliferation of quiescent human bone marrow cd34+ cd38~ cells and mantains progenitor cells in vitro. Blood. 1996; 87: 3563-70.
11. Gabbianelli M, Pelosi E, Montesoro E, Valtieri M, Luchetti L, Dsamoggia P, Vitelli L, Barben T, Testa U, Lyman S, Peschle C. Multi level effects of Flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomoocytic progenitors/monocytic precursors. Blood 1995; 86: 1661-70.
12. Hirayama F, Lyman SD, Clark SC, Ogawa M. The FH3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood 1995; 85: 1762-68.
13. Namikawa R, Muench MO, de Vries JE, Roncarolo MG. The Flk2/FIt3 ligand syergizes with interleukin-7 in promoting stromal-cell-independent expansion and differentiation of human fetal pro-B cells in vitro. Blood 1996; 87: 1881-90.
14. Jacobsen SEW, Okkenhaug C, Myklebust J, Veiby OP, Lyman SD. The Flt3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. I. Exp. Med. 1995; 181: 1357-63.
15. Molineux G, McCrea C, Van XQ, Kerzic P, McNiece I. FtD ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral lood stem cells with long term repopulating potential. Blood 1997; 89: 3998-4004.
16. McNiece I, Andrews R, Stewart M, Clark S, Boone T, Quesenbeny P. Action of interleukin-3, G-CSF, and GM-CSF on highly enriched human hematopoietic progenitor cells: synergistic interaction of GM-CSF plus G-CSF. Blood 1989; 74: 110-14.
17. Lopez AF, To LB, Yang YC, Gamble JR, Shanon MF, urns OF, Dyson PG, Tuttner CA, Clark S, Vadas MA. Stimulation of proliferation, differentiation, and functuion of human cells by primate interleukin-3. Proc. Natl. Acad. Sci. USA 1987; 84: 2761-65.
18. Rusthoven JJ, Eisenhauer E, Mazurka J, Hüte H, O Connell G, Muldal A, Lu HX, Onetto N, Swenerton K, Jeffrey J Phase I clinical trial of recombinant human interleukin-3 combined with carboplatin in the treatment of patients with recurrent ovarian carcinoma. Natl Cancer Inst 1993; 85: 823-25.
19. Ganser A, Lindemann A, Seipelt G, Ottmann OG, Herrmann F, Eder M, Frisch J, Schulz G, Mertelsmann R, Hoelzer D Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 1990; 76: 666-16.
20. Lindemann A, Ganser A, Errmann F, Frich J, Seipelt G, Schulz G, Holzer D, Mertelsmann R. Biologie effects of recombinant interleukin-3 in vivo. J. Clin. Oncol. 1991; 12. 2120-27.
21. Postmus PE, Gietema JA, Damsma O, Biesma B, Limburg PC, Vellenga E, deVriest EGE. Effects of recombinant human interleukin-3 in patients with relapsed small cell lung cancer treated with chemotherapy: a dose-finding study. J. Clin. Oncol. 1992; 10: 13310.
22. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N. Engl. J. Med. 1992; 327: 99-106.
23. Gasson JC. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991; 77: 1131-45.
24. Vadas MA, Nicola NA, Metcalf D. Activation of antibody dependent cell mediated cytotoxicity of human neutrophils and eosinophils by separate colony-stimulating factors. J. Immunol. 1983; 130:795-99.
25. Weisbart RH, Kacena A, Schuh A, Golde DW. GM-CSF induced human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature 1988,332:64748.
26. Aglietta M, Piacibello W, Sanavio F, Stacchini A, Apra F, Schena M, Mossetti C, Carnino F Caligaris-Cappio F, Gavosto F. Kinetics of human hemopoietic cells after in vivo administration ofgranulocyte-macrophage colony-stimulating factor. J Clin Invest 1995; 83: 551-57.
27. Aglietta M, Bussolino F, Piacibello W, Apra F, Sanavio F, Stacchini A, Monzeglio C, Carnino F, Gavosto F. Human GMCSF in vivo: identification of the target cells and of their kinetics of response. Int. J. Cell Cloning 1990; 8: 283-90.
28. Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232: 61-65.
29. Avalos BR, Gasson JC, Hedvat C, Quan SG, Baldwin GC, Weisbart RH, Willianis RE, Golde DW, DiPersio JF. Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. Blood 1990; 75: 851-57.
30. Platzer E, Weite K, Gabrilove JL, Lu L, Harris P, Mertelsmann R, Moore MA. Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells. J Exp Med 1985; 162: 1788-801.
31. Okabe T, Takaku F. In vivo granulocytopoietic activities of human recombinant granulocyte colony-stimulating factor. Exp. Hematol.1986; 14: 475-81.
32. Kaushansky K, Broudy VC, Lin N, Jorgensen MJ, McCarty J, Fox N, Zucher-Franklin D, Lofton-Day C. Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development. Proc. Natl. Acad. Sci. USA 1995; 92: 3234-38.
33. Kaushansky K, Broudy VC, Grossmann A, Humes J, Lin N, Ren HP, ailey MC, Papayannopoulou T, Forstrom J, Sprugel KH. Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J. Clin. Invest. 1995; 96: 1683-87.
34. Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M. Thrombooietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or ini:erleukin-3. Blood 1996; 88: 429-36.
35. Petzer AL, Zandstra PW, Iret JM, Eaves CJ. Differential cytochine effects on primitive (CD34+ CD38~) human hematopoietic cells: novel responses to FÜ3 ligand and thrombopoietin. J. Exp. Med. 1996; 183: 2551-58.
36. Bretti S, Gilleece MH, Karathan A, Fitzsimraons L, Hicks F, Rowlands M, Bishop P, Picardo AM, Dexter TM, Scarffe JH. An open phase I study to assess the biological effects of a continuous intravenous infusion of Interleukin-3 followed by Granulocyte Macrophage-Colony Stimulating Factor. Eur J Cancer, 1996; 32A: 1171-8
37. Scadden DT, Levine JD, Bresnahan J, Gère J, McGrath J, Wang Z, Resta DJ, Young D, Hammer SM. In vivo effects of interleukin 3 in HIV type 1-infected patients with cytopenia. AIDS Res Hum Retroviruses, 1995; 11: 731-40.
38. Younes A, Sarris A, Consoli U, Rodriguez A, McLaughlin P, Huh Y, Starry S, Cabanillas F Andreeff M. A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma; hématologie, immunologie, and clinical results. Blood, 1996, 87: 1698-703.
39. Cairo MS, Suen Y, Sender L, Gillan ER, Ho W, Plunkett JM, VandeVen C. Circulating granulocyte colony-stimulating factor (G-CSF) levels after allogeneic and autologous bone marrow transplantation: endogenous G-CSF production correlates with myeloid engraftment. Blood. 1992; 79: 1869-73.
40. Lieschke GJ, Burgess AW. Granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor (1). N. Engl: J. Med. 1992; 327: 28-35.
41. Neidhart JA. Hematopoietic colony-stimulating factors. Uses in combination with standard hemotherapeutic regimens and in support of dose intensification. Cancer. 1992; 70: 913-20.
42. Schriber JR, Chao NJ, Long GD, Negrin RS, Tierney DK, Kusnierz Glaz C, Lucas KS, Blume KG. Granulocyte colonystimulating factor after allogeneic bone marrow transplantation. Blood. 1994; 84: 1680-4.
43. Khwaja A, Mills W, Leveridge K, Goldstone AH, Linch DC. Efficacy of delayed granulocyte colony-stimulating factor after autologous BMT. Bone Marrow Transplant. 1993; 11:479-82.
44. Schriber JR, Chao NJ, Long GD, Negrin RS, Tierney DK, Kusnierz Glaz C, Lucas KS, Blume KG. Granulocyte colonystimulating factor after allogeneic bone marrow transplantation. Blood. 1994; 84: 1680-4.
45. Schuening FG, Nemunaitis J, Appelbaum FR, Storb R. Hematopoietic growth factors after allogeneic marrow transplantation in animal studies and clinical trials. Bone-MarrowTransplant. 1994; 14: 74-7.
46. Mire-Sluis AR, Das RO, Thorpe R: The international standard for g;ranulocyte colony stimulating factor (G-CSF). Evaluation in an international collaborative study. J. Immunol. Methods 1995; 179: 117-20.
47. Oisselbrecht C, Prentice O, Bacigalupo A, Biron P, Milpied N, Rubie H, Cunningham D, Legros M, Pico IL, Linch DC, Burnett AK, Scarffe IH, Siegert W, Yver A: A phase III randomised placebo-controlled study of lenograstim (glycosylated rHuGCSF) in 315 paediatric and adult autologous or allogeneic bone marrow transplant patients. Lancet 1994; 343: 696-702.
48. Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast RC, Gilbert CJ, Dette DH. Effect of recombinant human granulocyte-macrophage colonystimulating factor on hematopoietic reconstitution after high dose chemotherapy and autologous bone marrow transplantation. N. Engl. J. Med. 1988, 318: 869-76.
49. Rabinowe SN, Meuberg D, Bierman PJ, Vose JM, Nemuanatis J, Singer JW, Freedman AS, Mauch P, Demetri G, Onetto N, Gillis S, Oette D, Buckner D, Hansen JA, Ritz J, Armitage JO, Nadler LM, Applebaum FR. Long term follow up of a phase III study of recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation forlymphoid malignances. Blood. 1993; 81: 1903-08.
50. Khwaja A, Linch DC, Goldstone AH, Chopra R, Marcus RE, Wimperis JZ, Russell NH, Haynes AP, Milligan DW, Leyland MJ. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trial. Br.J.Haematol. 1992; 82: 317-23.
51. Gorin NC, Coiffier B, Hayat M, Fouillard L, Kuentz M, Flesch M, Colombat P, Boivin P, Slavin S, Philip T. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in nonHodgkin's lymphoma: a double-blind placebo-controlled trial. Blood. 1992; 80: 1149-57.
52. Aglietta M, Ardizzoni A, Avanzi GC, Conte PF, Galligioni E, Lorusso V, Luporini G, Mantovani A, Marangolo M, Miniero R, Moretta L, Parmiani G, Pergola M, Rosso R, Tarella C, Venturini M. GM-CSF in oncology: limits and possibilities. ANM consensus meeting. FORUM 1994; 4: 746-49.
53. Goodman Gilmans A, Rail TW, Nies AS, Taylor P. Goodman and Oilman's The pharmacological basis therapeutics 1997; p. 1317.
54. Civin 1C, Strauss LC, Brovall C, Fackler MJ, Schwartz H, Shaper JK. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-la cells. J. Immunol. 1984; 133: 157-65.
55. Brand J, Baird N, Lu L, Srour E, Huffman R. Characterization of a human progenitor cell capable of forming blast cell containing colonies in vitro. J. Clin. Invest. 1988; 82: 1017-24.
56. Tavassoli M, Hardy CL: Molecular basis of homing of intravenously transplanted stem cells. Blood 1990; 76: 1059-63.
57. Long MW: Blood cell cytoadhesion molecules. Exp. Hematol. 1992; 20: 288-92.
58. Simmons PI, Zannettino A, Oronthos S, Leavesley D: Potential adhesion mechanisms for localisation of haemopoictic progenitors to bone marrow stroma. Leuk. Lyrnphoma 1994; 12: 353-57.
59. Levesque IP, Haylock DN, Simmons PI. Cytokine regulation of proliferation and cell adhesion are correlated events in human CD34+ hemopoictic progenitors. Blood 1996; 88: 1168-73.
60. To LB, Haylock DN. Dowse T, Simmons PI, Trimboli S, Ashman LK. Juttner CA: A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34 cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34 cells. Blood 1994; 84: 2930-36.
61. To LB, Haylock DN, Kimler RJ, Juttner CA: High Levels of circulating hemopoietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection; and cryopreservation. Br. J. Haematol. 1984; 58: 399-404.
62. To LB, Sheppard KM, Haylock DN, Dyson PG, Charles P.Thorpe DL, Dale BM, Dart OW, Roberts MM, Sage RE, Jurtter CA. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoictic stem cells from the peripheral blood. Exp Hematol 1989; 88: 442-49.
63. Schwartzberg LS, Birch R, Hazelton B, Tauer KW, Lee P, Altemose MD, George C, Blanco R, Wittlin F, Cohen l, Muscato l, West WH. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J. Hematother 1992.; 1: 31723.
64. Haynes A. Hunter A. McQuaker 0, Anderson S, Bienz N, Russell NH: Engrafiment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant 16: 359, 1995.
65. Duhrsen U, Villeval J-L, Boyd I, Kannourakis 0, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colonystimulating factor on hematopoietic progertitor cjells in cancer patients. Blood 1988; 72: 2074-79.
66. Demuynck H, Pettengell R, decampos E, Dexter TM, Testa NO. The capacity of peripheral blood stem cells mobilized with chemotherapy plus G-CSF to repopulate irradiated marrow stroma in vitro is similar to that of bone marrow. Eur. J. Cancer 1992; 28: 381-87.
67. Sheridan WP, Begley CO, Juttner CA, Szer I, To LB, Mäher D, McGrath KM, Morstyti O, Fox RM. Effect of peripheral blood progenitor cells mobilized by fllgrastim (Cr-CSF) on platelet recovery after high does chemotherapy. Lancet 1992; 339: 640-648.
68. Hoglund M, Smedmyr B, Simonsson B, Totterman T, Bengtsson M: Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Bone Marrow Transplant. 1996; 18: 19-25.
69. Waller CF, Bertz H, Wenger MK, Fetscber S, Hardung M, Engelhardt M, Behringer D, Lange W, Mertelsmann R, Finke I. Mobilization of peripheral blood progenitor cells for allogencic transplantation: Efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplant 1996; 18: 279-85.
70. Hoglund M, Bengesson M, Cour-Chabemaud Y, DabouzHarrouche F, Simonsson B, Smedmyr B, Torrerman T. Glycosylated rHuG-CSF is more potent than non-glycosylatetl rHuG-CSF in mobilisation of peripheral blood progenitor cells (PB PC) in healthy volunteers. Blood 1995; 86:464a, (abstr, suppl 1).
71. Socinski MA, Cannistra SA, Elias A, Anttnan KI1, Schnipper L, Griffin ID: Granulocyte-macrophage colony-stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; 1: 1194-98.
72. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Piler A, Bonadonna 0. Granulocyte-macnophage colony-stimulating factor to harvest circulating hemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580-583.
73. Haas R, Ho AD, Bredthauer U, Cayeux, Egerer G. Knauf W, Hunstein W. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocytemacrophage colony-stimulating factors. Exp. Hematol. 1990; 18:94-99.
74. Villeval IL, Duhrsen U, Morstyn G, Metcalf D: Effect of recombinant human granulocyte-macrophage colony stimulating factor on progenitor cells in patients with advance malignancies. Br. J. Haematol. 1990; 74: 36-41.
75. Elias AD, Ayash L, Anderson KC, Hunt M, Wheeler C, Schwaztz O, Tepler I, Mazanet R, Lynch C, Pap S. Mobilization of peripheral blood progenitor cells by chemtherapy and granulocyte macrophage colony stimulating factor for hématologie support after high dose intensification for breast cancer. Blood 1992; 79: 3036-41.
76. Peters WP, Rosner G, Ross M, Vredenburgh I, Meisenberg B, Gilbert C, Kurtzberg I. Comparative effects of granulocytemacrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-14.
77. Bolwell BJ, Goormastic M, Yanssens T, Dannley R, Baucco P, Fishleder A. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. Bone Marrow Transplant. 1994; 14:913-8.
78. Koller MR, Emerson SG, Palsson BO. Large scale expansion of human stem and progeitor cells from bone marrow mononuclear cells in continuous perfusion culturels. Blood 1993; 82: 378-84.
79. Lemieux ME, Rebel VI, Lansdorp PM, Eaves CJ. Characterization and purification of a primitive hematopoietic cell type in adult mouse marrow capable of lymphomyeloid differentiation in long-term marrow "switch" cultures. Blood 1995; 86: 1339-47.
80. Sutherland HJ, Lansdorp PM, Henkelman DH, Eaves AC, Eaves CJ. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc. Natl. Acad. Sci. USA 1990; 87: 3584-88.
81. Ploemacher RE, van der Sluijs JP, van Beurden CA, Baert MR, Chan PL. Use of limiting-dilution type long-term marrow cultures in frequency analysis of marrow-repopulating and spleen colony-forming hematopoietic stem cells in the mouse. Blood 1991; 78: 2527-33.
82. Hogge DE, Lansdorp PM, Reid D, Gerhard B, Eaves CJ. Enhanced detection maintenance and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor. Blood 1996; 88: 3765-73.
83. Lansdorp PM, Dragowska W. Long-term erythropoiesis from constant numbers of CD34+ cells in serum-free cultures initiated with highly purified progenitor cells from human bone marrow. J. Exp. Med. 1992; 175: 1501-509.
84. Sauvageau G, Lansdorp PM, Eaves CJ, Hogge DE, Dragowska WH, Reid DS, Largman C, Lawrence HJ, Humphries RK. Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Proc. Natl. Acad. Sci. USA 1994; 91: 12223-27.
85. Petzer AL, Hogge DE, Landsdorp PM, Reid DS, Eaves CJ. Self-renewal of primitive human hematopoietic cells (longterm-culture-initiating cells) in vitro and their expansion in defined medium. Proc. Natl. Acad. Sci. USA 1996; 93: 147074.
86. Piacibello W, Sanavio F, Garetto L, Severino A, Bergandi D, Ferrario J, Fagioli F, Berger M, Aglietta M. Extensive amplification and self renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997; 89: 2644-53.